Challenges of antibacterial discovery revisited

Annals of the New York Academy of Sciences

Volumn 1213, Issue 1, 2010, Pages 5-19

  Gwynn, Michael N ^a   Portnoy, Alison ^a   Rittenhouse, Stephen F ^a   Payne, David J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antibacterial discovery; Boron chemistry; DNA encoded library; Gene essentiality; HTS; Novel antibiotic

Indexed keywords

ANTIINFECTIVE AGENT; ENZYME INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; NONHUMAN;

BACTERIA (MICROORGANISMS);

EID: 78650357755     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05828.x     Document Type: Article

References (104)

1. Fischbach, M.A. & C.T. Walsh 2009. Antibiotics for emerging pathogens. Science 325: 1089-1093.
2. Infectious Diseases Society of America. 2004. Bad bugs, no drugs: as antibiotic R&D stagnates, a public health crisis brews, (accessed October 23, 2010).
3. Talbot, G.H., J. Bradley Jr., J.E. Edwards et al. 2006. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42: 657-668.
4. Fernandes, P. 2006. Antibacterial discovery and development-the failure of success? Nat. Biotechnol. 24: 1497-1503.
5. Lange, R.P., H.H. Locher, C.P. Wyss et al. 2007. The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Design 13: 3140-3154.
6. Royal Society Policy Document. 2008. Innovative mechanisms for tackling antibacterial resistance, (accessed October 23, 2010).
7. Spellberg, B., J.H. Powers, E.P. Brass et al. 2004. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38: 1279-1286.
8. Payne, D.J., M.N. Gwynn, D.J. Holmes et al. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6: 29-40.
9. IDSA. 2008. Challenges in the pathway to antibiotic approvals. (accessed October 23, 2010).
10. DiMasi, J.A., R.W. Hansen & H.G. Grabowski 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22: 151-185.
11. Schurek, K.N., R. Wiebe, J.A. Karlowsky et al. 2007. Faropenem: review of a new oral penem. Expert Rev. AntiInfect. 5: 185-198.
12. Theuretzbacher, U. 2009. Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob. Agents 34: 15-20.
13. Mitscher, L.A. 2005. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev. 105: 559-592.
14. Black, M.T., T. Stachyra, D. Platel et al. 2008. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob. Agents Chemother. 52: 3339-3349.
15. Bax, B.D., P.F. Chan, D.S. Eggleston et al. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466: 935-940.
16. Miller A.A., G.L. Bundy, J.E. Mott et al. 2008. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob. Agents Chemother. 8: 2806-2812.
17. Novak R. & D.M. Shlaes 2010. The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Invest. Drugs 11: 182-191.
18. Ochsner, U.A., X. Sun, T. Jarvis et al. 2007. Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Expert Opin. Inv. Drug. 16: 573-593.
19. Gilbert, J., P. Henske & A. Singh 2003. Rebuilding big pharma's business model. Business Med. Rep. (accessed October 23, 2010).
20. Hughes, D. 2003. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Genet. 4: 432-441.
21. NCBI Genome Project. (accessed October 23, 2010).
22. Lock, R.L., & E.J. Harry 2008. Cell-division inhibitors: new insights for future antibiotics. Nat. Rev. Drug Discov. 7: 324-338.
23. Gentry, D.R., K.A. Ingraham, M.J. Stanhope et al. 2003. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob. Agents Chemother. 47: 1784-1789.
24. Payne, D.J., W.H. Miller, V. Berry et al. 2002. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents.Chemother. 46: 3118-3124.
25. Du, W., J.R. Brown, D.R. Sylvester et al. 2000. Two active forms of UDP-N-Acetylglucosamine enolpyruvyl transferase in Gram-positive bacteria. J. Bacteriol. 182: 4146-4152.
26. Harris, S.R., E.J. Feil, M.T.G. Holden et al. 2010. Evolution of MRSA during hospital transmission and intercontinental spread. Science 327: 469-474.
27. Brinster, S., G. Lamberet, B. Staels et al. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458: 83-86.
28. Balemans, W., N. Lounis, R. Gilissen et al. 2010. Essentiality of FASII pathway for Staphylococcus aureus [arising from Nature, 2009, 458: 83-86]. Nature 463: E3.
29. Brinster, S., G. Lamberet, B. Staels et al. 2010. Replying to W. Balemans et al. 2009, Nature 463: E3. Nature 463: E4.
30. Blundell, T.L., H. Jhoti & C. Abell 2002. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1: 45-54.
31. Arkin, M.R. & J.A. Wells 2004. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3: 301-317.
32. Haydon, D.J., N.R. Stokes, R. Ure et al. 2008. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321: 1673-1675.
33. Silver, L.L. 2008. Does the cell wall of bacteria remain a viable source of targets for novel antibiotics. Biochem. Pharmacol. 71: 996-1005.
34. Stachyra, T., P. Levasseur, M.-C. Péchereau et al. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemoth. 64: 326-329.
35. Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264: 382-388.
36. Page, M.G.P. & J. Heim 2009. Prospects for the next anti-Pseudomonas drug. Curr. Opin Pharmacol. 9: 558-565.
37. Silver, L.L. & K.A. Bostian 1993. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother. 37: 377-383.
38. Gualtieri, M., F. Baneres-Roquet, P. Villain-Guillot et al. 2009. The antibiotics in the chemical space. Curr. Med. Chem. 16: 390-393.
39. Drewry, D.H. & R. Macarron 2010. Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr. Opin. Chem. Biol. 14: 289-298.
40. Hann, M.M., A.R. Leach & G. Harper 2001. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Model. 41: 856-864.
41. Snowden, M.A. & D.V.S. Green 2008. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind." Curr. Opin. Drug Dis. Dev. 11: 553-558.
42. Tan, D.S. 2005. Diversity oriented synthesis: exploring the intersections between chemistry and biology. Nat. Chem. Biol. 1: 74-84.
43. Galloway, W.R.J.D., A. Bender, M. Welch & D.R. Spring 2009. The discovery of antibacterial agents using diversity-oriented synthesis. Chem. Commun. 18: 2446-2462.
44. Jacoby, E. & A. Mozzarelli 2009. Chemogenomic strategies to expand the bioactive chemical space. Curr. Med. Chem. 16: 4374-4381.
45. Newman, D.J. & G.M. Cragg 2007. Natural products as sources of new drugs over the last 25 years. J. Nat. Products 70: 461-477.
46. Butler, M.S. & A.D. Buss 2006. Natural products-the future scaffolds for novel antibiotics? Biochem. Pharmacol. 71: 919-929.
47. Pelaez, F. 2006. The historical delivery of antibiotics from microbial natural products-can history repeat? Biochem. Pharmacol. 71: 981-990.
48. Li, J.W.H. & J. C. Vederas 2009. Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
49. Feher, M. & J.M. Schmidt 2003. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Model. 43: 218-227.
50. Koehn, F.E. & G.T. Carter 2005. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4: 206-220.
51. Baltz, R.H. 2008. Renaissance in antibacterial discovery from actinomycetes. Curr. Opin. Pharmacol. 8: 557-563.
52. Chetan S.C.K., J.L. Jenkins, R.E.J. Beckwith et al. 2009. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. J. Biomol. Screen. 14: 690-699.
53. Nielsen, F.H. 2009. Micronutrients in parenteral nutrition: boron, silicon, and fluoride. Gastroenterology 137: S55-S60.
54. Baker, S.J., C.Z. Ding, T. Akama et al. 2009. Therapeutic potential of boron-containing compounds. Future Med. Chem. 1: 1275-1288.
55. Systemic Anti-Infectives Pipeline. Anacor Pharmaceuticals. 2009. (accessed October 23, 2010).
56. Rock, F.L., W. Mao, A. Yaremchuk et al. 2007. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316: 1759-1761.
57. Seiradake, E., W. Mao, V. Hernandez et al. 2009. Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles. J. Mol. Biol. 390: 196-207.
58. Clark, M.A., R.A. Acharya, C.C. Arico-Muendel et al. 2009. Design, synthesis and selection of DNA-encoded small-molecule libraries. Nat. Chem. Biol. 5: 647-654.
59. Chessari, G. & A.J. Woodhead 2009. From fragment to clinical candidate-a historical perspective. Drug Discov. Today 14: 668-675.
60. Mochalkin, I., J.R. Miller, L. Narasimhan et al. 2009. Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem. Biol. 4: 473-483.
61. Brotz-Oesterhelt, H., D. Beyer, H.-P. Kroll et al. 2005. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11: 1082-1087.
62. Gentry, D.R., I. Wilding, J.M. Johnson et al. 2010.A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential. J. Microbiol. Methods. 83: 254-256.
63. Stokes, N.R., J. Sievers, S. Barker et al. 2005. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J. Biol. Chem. 280: 39709-39715.
64. Wang, J., S.M. Soisson, K. Young et al. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
65. Miesel, L., J. Greene & T.A. Black 2003. Genetic strategies for antibacterial drug discovery. Nat. Rev. Genet. 4: 442-456.
66. Andries, K., V. Peter, J. Guillemont et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
67. Pathania, R., S. Zlitni, C. Barker et al. 2009. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat. Chem. Biol. 5: 849-856.
68. Miller, J.R., S. Dunhama, I. Mochalkin et al. 2009. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl. Acad. Sci. USA 106: 1737-1742.
69. Poole, K. 2007. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 39: 162-176.
70. Lomovskaya, O., H.I. Zgurskaya, M. Totrov & W.J. Watkins 2007. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat. Rev. Drug Discov. 6: 56-66.
71. Lomovskaya, O. & K.A. Bostian 2006. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem. Pharmacol. 71: 910-918.
72. Surawicz, C.M. 2005. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy 51(Suppl. 1): 81-89.
73. Kelly, C.P., C. Pothoulakis & J.T. LaMont 1994. Clostridium difficile colitis. N. Engl. J. Med. 330: 257-262.
74. Bartlett, J.G. 1992. Antibiotic-associated diarrhea. Clin. Infect. Dis. 15: 573-579.
75. Bouza, E., A. Burillo & P. Munoz 2006. Antimicrobial therapy of Clostridium difficile-associated diarrhea. Med. Clin. North Am. 90: 1141-1163.
76. Credito, K.L. & P.C. Appelbaum 2004. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48: 4430-4434.
77. Finegold, S.M., D. Molitoris, M.-L. Vaisanenet et al. 2004. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob. Agents Chemother. 48: 4898-4902.
78. Larson, H.E. & S.P. Borriello 1990. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob. Agents Chemother. 34: 1348-1353.
79. Shue, Y.K., P.S. Sears, S. Shangle et al. 2008. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52: 1391-1395.
80. Lowry, I., D.C. Molrine, B.A. Leav et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362: 197-205.
81. Bebbington, C. & G. Yarranton 2008. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr. Opin. Biotech. 19: 613-619.
82. Obrecht, D., J.A. Robinson, F. Bernardini et al. 2009. Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics. Curr. Med. Chem. 16: 42-65.
83. Srinivas, N., P. Jetter, B.J. Ueberbacher et al. 2010. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327: 1010-1013.
84. Wimberly, B.T. 2009. The use of ribosomal crystal structures in antibiotic drug design. Curr. Opin. Invest. Drugs 10: 750-765.
85. Augmentin label approved 12/04/2008. 2008. FDA.gov (accessed October 23, 2010).
86. Avandia label approved 10/20/2008. 2008. FDA.gov (accessed October 23, 2010).
87. Werner, A.L. & M.T. Travaglini 2001. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21: 1082-1099.
88. Imitrex label approved 10/13/2004. 2004. FDA.gov (accessed October 23, 2010).
89. Perry, C.M. & M. Anthony 1998. Sumatriptan. An updated review of its use in migraine. Drugs 55: 889-922.
90. Lasser, K.E., P.D. Allen, S.J. Woolhandler et al. 2002. Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287: 2215-2220.
91. Raschi, E., L. Ceccarini, F. De Ponti & M. Recanatini 2009. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin. Drug Metab. Toxicol. 5: 1005-1021.
92. Chaudhary, K.W. & B.S. Brown 2010. Assessment of strategies utilized to minimize the potential for induction of acquired long QT syndrome and torsade de pointes. In Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology, Vol. 10. C. Han, B.D. Charles & B. Wang, Eds.: 253-278. John Wiley & Sons, Inc. Hoboken
93. Leeson, P.D. & A.M. Davis 2004. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 47: 6338-6348.
94. Leeson, P.D. & B. Springthorpe 2007. The influence of drug-like concepts on decision-making in medician chemistry. Nat. Rev. Drug Discov. 6: 881-890.
95. Czock, D., B. Hartman & F. Keller 2009. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin. Drug Metab. Toxicol. 5: 475-487.
96. Andes, D. & W.A. Craig 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19: 261-288.
97. Courvalin, P. 2008. Can pharmacokinetic-pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance? Clin. Microbiol. Infect. 14: 989-994.
98. Drusano, G.L., S.L. Preston, C. Hardalo et al. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45: 13-22.
99. Bhavnani, S.M., J.P. Hammel, B.B. Cirincione et al. 2005. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 49: 3944-3947.
100. Andes, D., M.L. van Ogtrop, J. Peng et al. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46: 3483-3489.
101. Pertel, P.E., P. Bernardo, C. Fogarty et al. 2008. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin. Infect. Dis. 46: 1142-1151.
102. Silverman, J.A., L.I. Mortin, A.D.G. VanPraagh et al. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. 191: 2149-2152.
103. Guidos, R.J. 2009. New Transatlantic Task Force on Antimicrobial Resistance: A Path Forward (accessed October 23, 2010).
104. Infectious Diseases Society of America. Bad Bugs, No Drugs ... 10 New Antibiotics by 2020, (accessed October 23, 2010).